Scarica l'app Stockscreener
22.84
2.15%
0.48
Pre-mercato:
23.59
0.75
+3.28%
Precedente Chiudi:
$22.36
Aprire:
$22.23
Volume 24 ore:
858.92K
Relative Volume:
1.25
Capitalizzazione di mercato:
$1.05B
Reddito:
$681.75M
Utile/perdita netta:
$70.47M
Rapporto P/E:
15.75
EPS:
1.45
Flusso di cassa netto:
$173.19M
1 W Prestazione:
+11.14%
1M Prestazione:
+20.34%
6M Prestazione:
+17.91%
1 anno Prestazione:
-28.27%
Intervallo 1D:
$21.84
$22.88
Intervallo di 1 settimana:
$20.33
$22.88
Portata 52W:
$11.16
$34.01
Pacira Biosciences Inc Stock (PCRX) Company Profile
Nome
Pacira Biosciences Inc
Settore
Telefono
813-553-6680
Indirizzo
5401 WEST KENNEDY BOULEVARD, TAMPA, NJ
Confronta PCRX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PCRX
Pacira Biosciences Inc
|
22.84 | 1.05B | 681.75M | 70.47M | 173.19M | 1.45 |
|
ZTS
Zoetis Inc
|
167.53 | 75.58B | 9.15B | 2.43B | 2.31B | 5.32 |
|
HLN
Haleon Plc Adr
|
9.24 | 41.78B | 14.26B | 1.55B | 0 | 0.3383 |
|
TAK
Takeda Pharmaceutical Co Adr
|
13.10 | 41.53B | 30.27B | 1.93B | 3.45B | 0.6044 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
21.82 | 24.72B | 16.77B | -959.00M | 1.37B | -0.85 |
|
NBIX
Neurocrine Biosciences Inc
|
145.88 | 14.77B | 2.24B | 385.90M | 440.10M | 3.73 |
Pacira Biosciences Inc Stock (PCRX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-08-13 | Downgrade | Truist | Buy → Sell |
| 2024-08-12 | Downgrade | JP Morgan | Overweight → Underweight |
| 2024-08-12 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2024-08-12 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-08-12 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2024-07-03 | Downgrade | Barclays | Overweight → Equal Weight |
| 2024-03-07 | Ripresa | JP Morgan | Overweight |
| 2023-12-20 | Iniziato | Raymond James | Outperform |
| 2023-08-03 | Aggiornamento | TD Cowen | Market Perform → Outperform |
| 2023-01-31 | Ripresa | Wedbush | Outperform |
| 2022-10-21 | Ripresa | Jefferies | Buy |
| 2022-01-03 | Ripresa | JP Morgan | Overweight |
| 2021-07-26 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2021-04-21 | Ripresa | JP Morgan | Neutral |
| 2021-04-09 | Iniziato | Berenberg | Buy |
| 2021-04-07 | Ripresa | RBC Capital Mkts | Outperform |
| 2021-02-11 | Downgrade | Northland Capital | Outperform → Market Perform |
| 2021-01-21 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2020-09-21 | Aggiornamento | Northland Capital | Market Perform → Outperform |
| 2020-07-06 | Reiterato | Needham | Buy |
| 2020-05-27 | Iniziato | Guggenheim | Neutral |
| 2020-04-07 | Iniziato | Northland Capital | Outperform |
| 2020-03-20 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2020-02-24 | Reiterato | H.C. Wainwright | Buy |
| 2020-01-24 | Iniziato | SunTrust | Buy |
| 2020-01-23 | Iniziato | SunTrust | Buy |
| 2019-11-06 | Iniziato | BTIG Research | Buy |
| 2019-06-11 | Iniziato | Barclays | Overweight |
| 2019-05-06 | Aggiornamento | Mizuho | Underperform → Neutral |
| 2019-05-02 | Aggiornamento | Stifel | Sell → Hold |
| 2019-02-01 | Downgrade | Mizuho | Neutral → Underperform |
| 2018-08-06 | Downgrade | BofA/Merrill | Buy → Neutral |
| 2018-04-09 | Reiterato | H.C. Wainwright | Buy |
| 2018-03-21 | Reiterato | Mizuho | Neutral |
| 2018-02-16 | Downgrade | Needham | Buy → Hold |
| 2018-01-19 | Iniziato | Seaport Global Securities | Buy |
| 2018-01-04 | Reiterato | Canaccord Genuity | Buy |
| 2018-01-03 | Iniziato | Leerink Partners | Mkt Perform |
Mostra tutto
Pacira Biosciences Inc Borsa (PCRX) Ultime notizie
Pacira BioSciences, Inc. (NASDAQ:PCRX) Receives $24.50 Average Price Target from Analysts - Defense World
PACIRA BIOSCIENCES SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & ... - The Bakersfield Californian
PACIRA BIOSCIENCES SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Pacira BioSciences, Inc. - GlobeNewswire Inc.
ROSEN, A LEADING LAW FIRM, Encourages Pacira BioSciences, - GlobeNewswire
ROSEN, A LEADING LAW FIRM, Encourages Pacira BioSciences, Inc. Investors to Secure Counsel - The Bakersfield Californian
ROSEN, A LEADING LAW FIRM, Encourages Pacira BioSciences, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – PCRX - GlobeNewswire Inc.
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Pacira Biosciences, Inc. of Class Action Lawsuit and Upcoming DeadlinesPCRX - PR Newswire
Pacira Pharmaceuticals Announces Leadership Changes and Plan Amendment - TipRanks
Pacira BioSciences Strengthens Executive Leadership Team with Two Key Appointments - GlobeNewswire
Pacira BioSciences Strengthens Leadership Team with Two Strategic Executive Appointments - StockTitan
Pacira BioSciences, Inc. Class Action: Levi & Korsinsky Reminds - GuruFocus.com
Pacira BioSciences, Inc. Class Action: Levi & Korsinsky Reminds Pacira Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 14, 2025PCRX - Victoria Advocate
PCRX Investors Have Opportunity to Lead Pacira BioSciences, Inc. Securities Fraud Lawsuit - Longview News-Journal
PCRX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Pacira BioSciences, Inc. Shareholders with Losses Have Opportunity to Lead Class Action Lawsuit! - Markets Insider
Pacira BioSciences, Inc. Sued for Securities Law ViolationsInvestors Should Contact The Gross Law Firm for More InformationPCRX - Marketscreener.com
Assenagon Asset Management S.A. Trims Stock Holdings in Pacira BioSciences, Inc. (NASDAQ:PCRX) - MarketBeat
Assenagon Asset Management S.A. Sells 101,021 Shares of Pacira BioSciences, Inc. (NASDAQ:PCRX) - Defense World
Pacira BioSciences, Inc. (NASDAQ:PCRX) Given Consensus Rating of "Hold" by Brokerages - MarketBeat
Zacks Research Analysts Increase Earnings Estimates for PCRX - Defense World
PACIRA BIOSCIENCES SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Pacira - Kilgore News Herald
Lowey Dannenberg Notifies Pacira Biosciences, Inc. - GlobeNewswire
PCRX INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Pacira BioSciences, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - Business Wire
Zacks Research Has Positive Outlook of PCRX FY2024 Earnings - MarketBeat
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of March 14, 2025 in Pacira LawsuitPCRX - Morningstar
PCRX Investors Have Opportunity to Lead Pacira BioSciences, Inc. Securities Fraud Lawsuit with the Schall Law Firm - Kilgore News Herald
(PCRX) On The My Stocks Page - Stock Traders Daily
Investors in Pacira BioSciences, Inc. Should Contact Levi & - GlobeNewswire
PACIRA BIOSCIENCES SHAREHOLDER ALERT: CLAIMSFILER REMINDS - GlobeNewswire
Millennium Management LLC's Strategic Acquisition of Pacira BioS - GuruFocus.com
ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages - GlobeNewswire
The Gross Law Firm Notifies Shareholders of Pacira - GlobeNewswire
PACIRA BIOSCIENCES SHAREHOLDER ALERT by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Reminds Investors With Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Pacira BioSciences, Inc.PCRX - Business Wire
SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pacira - Marketscreener.com
PCRX INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC - GlobeNewswire
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pacira - GlobeNewswire
Stockholder Notice: Robbins LLP Informs Stockholders of the Pacira BioSciences, Inc. Class Action Lawsuit - PR Newswire
PCRX Stock Rises 11% on Upbeat Q4 Preliminary Product Sales - MSN
Pacira Patent Void Surprised Investors to Big Selloff, Suit Says - Bloomberg Law
Pacira BioSciences (NASDAQ:PCRX) Earns Sector Perform Rating from Royal Bank of Canada - MarketBeat
SHAREHOLDER ALERT: Class Action Lawsuit Filed on Behalf of - GlobeNewswire
2025-01-14 | PCRX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Pacira BioSciences, Inc. Stockholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! | NDAQ:PCRX | Press Release - Stockhouse Publishing
Pacira BioSciences (NASDAQ:PCRX) Given New $30.00 Price Target at Needham & Company LLC - Defense World
PCRX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Pacira BioSciences, Inc. Stockholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - Markets Insider
PCRX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Pacira BioSciences, Inc. Shareholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - AccessWire
Rosen Law Firm Urges Pacira BioSciences, Inc. (NASDAQ: PCRX) Stockholders with Large Losses to Contact the Firm for Information About Their Rights - The Bakersfield Californian
2025-01-13 | PCRX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Pacira BioSciences, Inc. Shareholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! | NDAQ:PCRX | Press Release - Stockhouse Publishing
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors - GlobeNewswire
6 Analysts Assess Pacira BioSciences: What You Need To Know - Benzinga
Pacira Pharmaceuticals, Inc. Provides Revenue Guidance for the Fourth Quarter and Full-Year of 2014 - Marketscreener.com
Pacira BioSciences (NASDAQ:PCRX) Shares Gap Up – Time to Buy? - Defense World
Pacira BioSciences (NASDAQ:PCRX) Shares Gap UpWhat's Next? - MarketBeat
Pacira Biosciences Inc Azioni (PCRX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.14%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):